company background image
ALGS

Aligos Therapeutics NasdaqGS:ALGS Stock Report

Last Price

US$0.91

Market Cap

US$39.1m

7D

-5.4%

1Y

-92.1%

Updated

08 Dec, 2022

Data

Company Financials +
ALGS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ALGS Stock Overview

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.

Aligos Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aligos Therapeutics
Historical stock prices
Current Share PriceUS$0.91
52 Week HighUS$13.11
52 Week LowUS$0.86
Beta1.93
1 Month Change-3.12%
3 Month Change-30.83%
1 Year Change-92.12%
3 Year Changen/a
5 Year Changen/a
Change since IPO-93.85%

Recent News & Updates

Recent updates

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Jul 11
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Feb 02
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

May 01
We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Jan 16
What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Shareholder Returns

ALGSUS BiotechsUS Market
7D-5.4%0.5%-2.8%
1Y-92.1%-8.6%-19.6%

Return vs Industry: ALGS underperformed the US Biotechs industry which returned -11.2% over the past year.

Return vs Market: ALGS underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is ALGS's price volatile compared to industry and market?
ALGS volatility
ALGS Average Weekly Movement9.6%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: ALGS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ALGS's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201889Larry Blatthttps://www.aligos.com

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH).

Aligos Therapeutics, Inc. Fundamentals Summary

How do Aligos Therapeutics's earnings and revenue compare to its market cap?
ALGS fundamental statistics
Market CapUS$39.09m
Earnings (TTM)-US$111.87m
Revenue (TTM)US$10.74m

3.6x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALGS income statement (TTM)
RevenueUS$10.74m
Cost of RevenueUS$94.58m
Gross Profit-US$83.84m
Other ExpensesUS$28.04m
Earnings-US$111.87m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.61
Gross Margin-780.83%
Net Profit Margin-1,041.95%
Debt/Equity Ratio0%

How did ALGS perform over the long term?

See historical performance and comparison